Clinical Trials

A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors


Study ID
Seattle Genetics SGN2FF-001

NCT Number
NCT02952989 (Click on the NCT number for more information about the trial)

Research Study Number
2016-0653

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Seattle Genetics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now